Project Sage Oldco 配当と自社株買い

配当金基準チェック /06

Project Sage Oldco配当金を支払った記録がありません。

主要情報

n/a

配当利回り

-4,821.7%

バイバック利回り

総株主利回り	-4,821.7%
将来の配当利回り	n/a
配当成長	n/a
次回配当支払日	n/a
配当落ち日	n/a
一株当たり配当金	n/a
配当性向	n/a

最近の配当と自社株買いの更新

更新なし

Recent updates

FDA approves Sientra’s breast implant product for breast augmentation, reconstruction

Jul 06

Sientra (NASDAQ:SIEN) Is Carrying A Fair Bit Of Debt

Apr 16

Is Sientra (NASDAQ:SIEN) Using Too Much Debt?

Jan 06

決済の安定と成長

配当データの取得

安定した配当: SIEN.Qの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。

増加する配当: SIEN.Qの配当金が増加しているかどうかを判断するにはデータが不十分です。

配当利回り対市場

Project Sage Oldco 配当利回り対市場

SIEN.Q 配当利回りは市場と比べてどうか？
セグメント	配当利回り
会社 (SIEN.Q)	n/a
市場下位25% (US)	1.3%
市場トップ25% (US)	4.3%
業界平均 (Medical Equipment)	1.7%
アナリスト予想 (SIEN.Q) (最長3年)	n/a

注目すべき配当: SIEN.Qは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。

高配当: SIEN.Qは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。

株主への利益配当

収益カバレッジ: SIEN.Qの配当性向を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。

株主配当金

キャッシュフローカバレッジ: SIEN.Qが配当金を報告していないため、配当金の持続可能性を計算できません。

Project Sage Oldco 配当と自社株買い

配当金 基準チェック /06

主要情報

最近の配当と自社株買いの更新

Recent updates

Second Amended Liquidation Plan Approved for Sientra, Inc.

Second Amended Combined Joint Reorganization Plan and Disclosure Statement Filed by Sientra, Inc.

First Motion for Exclusivity Period Extension Filed by Sientra, Inc.

Joint Reorganization Plan and Disclosure Statement Filed by Sientra, Inc.

Reorganization Plan and Disclosure Statement Filed by Sientra, Inc.

The Nasdaq Stock Market to Delist the Common Stock of Sientra

Sientra, Inc. announced delayed annual 10-K filing

Sientra, Inc. announced delayed annual 10-K filing

Sientra, Inc.(OTCPK:SIEN.Q) dropped from NASDAQ Composite Index

DIP Financing Approved for Sientra, Inc.

Motion for Asset Sale Filed by Sientra, Inc.

Sientra, Inc. Filed for Bankruptcy

Sientra, Inc. Filed for Bankruptcy

Sientra Receives Non-Compliance Notice from Nasdaq

Consensus EPS estimates fall by 15%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Market cap size

Sientra, Inc. Provides Revenue Guidance for the Third Quarter of 2023

Sientra, Inc. Revises Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Sientra, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Sientra, Inc. Appoints Alexander W. Casdin to the Company’s Board of Directors, Effective June 15, 2023

Sientra Announces FDA-Clearance of Next Generation Allox2 Pro Tissue Expander

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Sientra, Inc. Provides Earnings Guidance for the Full Year of 2023

Fewer Investors Than Expected Jumping On Sientra, Inc. (NASDAQ:SIEN)

Full year 2022 earnings: EPS misses analyst expectations

Sientra, Inc. Announces Launch of Viality, Novel Fat Transfer System

Insider recently bought US$933k worth of stock

Price target decreased to US$2.08

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Sientra, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Sientra, Inc. has completed a Follow-on Equity Offering in the amount of $29.217384 million.

Sientra slides 18% on proposes stock offering

Sientra, Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2022

Sientra refinances convertible debt at heavy premiums, sees Q3 revenue in-line

Sientra Receives Written Notice from the Listing Qualifications Department of Nasdaq

Sientra Receives Regulatory Approval to Market Breast Implants in Saudi Arabia

Sientra gets regulatory nod to market breast implants in Saudi Arabia

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Sientra, Inc. Revises Revenue Guidance for the Year 2022

Sientra GAAP EPS of -$0.29 misses by $0.06, revenue of $21.5M misses by $2.26M

Sientra, Inc. to Report Q2, 2022 Results on Aug 11, 2022

FDA Approves Sientra’s Low Plus Profile Projection Breast Implant

FDA approves Sientra’s breast implant product for breast augmentation, reconstruction

Sientra, Inc.(NasdaqGS:SIEN) dropped from Russell 2000 Dynamic Index

Price target decreased to US$6.33

Sientra, Inc. Provides Earnings Guidance for the Year 2022

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$6.83

Sientra, Inc. to Report Q1, 2022 Results on May 12, 2022

Sientra, Inc., Annual General Meeting, Jun 09, 2022

Price target decreased to US$7.67

Sientra (NASDAQ:SIEN) Is Carrying A Fair Bit Of Debt

Consensus EPS estimates fall by 31%

Price target decreased to US$10.60

Sientra, Inc. Provides Preliminary Unaudited Financial Results for the Fourth Quarter and Full Year Ended December 31, 2021

Is Sientra (NASDAQ:SIEN) Using Too Much Debt?

Third quarter 2021 earnings released: US$0.097 loss per share (vs US$0.12 loss in 3Q 2020)

Lead Independent Director Nicholas Simon has left the company

Sientra, Inc. Increases Earnings Guidance for the Full Year 2021

Second quarter 2021 earnings released: US$0.32 loss per share (vs US$0.68 loss in 2Q 2020)

1315 Capital, LLC completed the acquisition of miraDry business of Sientra, Inc. (NasdaqGS:SIEN).

決済の安定と成長

配当利回り対市場

株主への利益配当

株主配当金

高配当企業の発掘

配当金基準チェック /06